United States: AstraZeneca to pay US$5.52 million to resolve SEC foreign bribery case
Author(s): Nate Raymond | Date: August 30, 2016 | Language: English
Source: http://www.reuters.com/ | URL: http://goo.gl/va6Ekv | Type: Text
U.S. regulators said on Tuesday that AstraZeneca Plc (AZN.L) will pay $5.52 million to resolve a foreign bribery probe into improper payments by its sales and marketing staff to state-employed healthcare officials in China and Russia.
The U.S. Securities and Exchange Commission detailed the settlement with the London-based drug company in an order instituting an administrative proceeding arising out of violations of provisions in the Foreign Corrupt Practices Act.
AstraZeneca, which cooperated with the probe, neither admitted nor denied wrongdoing. In a statement, it said the U.S. Justice Department has meanwhile closed a related foreign bribery investigation.
This is a text block. Click the edit button to change this text..